Creating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.
Bill Woywod
Advertisement
Articles by Bill Woywod
How machine learning can provide an on-demand portfolio-wide view of optimal provider targeting and related field deployment.
Advertisement
Latest Updated Articles
How Machine Learning Gives Life Sciences Sales a Competitive AdvantagePublished: November 22nd 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
Bob Mauch: Strengthening the Chain
3
The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations
4
What Impact will DTC Programs Have on Prescription Drug Prices?
5
